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Neural cell transplantationand gene therapy have attracted considerable interest as promising therapeutic alternatives for patients
with Parkinson’s disease (PD).Preclinical and open-label studies have suggested that grafted fetal neural tissue or viral vector gene
transfer can achieve considerable biochemical and clinical improvements, whereas subsequent double-blind, placebo-controlled
protocols have produced rather more modest and variable results. Detailed evaluationof these discordant ﬁndings has highlighted
several crucial issues such as patient selection criteria, details surrounding transplantation or gene therapy methodologies, as well
as the study designs themselves that ought to be carefully considered in the planning phases of future clinical trials. Beyond the
provision of symptomatic eﬃcacy and safety data, it also remains to be identiﬁed whether the possibilities oﬀered by stem cell and
gene therapy technological advances might translate to meaningful neuroprotection and/or disease-modifying eﬀects or alleviate
the nonmotor aspects of PD and thus oﬀer additional beneﬁts beyond those achieved through conventional pharmacotherapy or
deep brain stimulation (DBS).
1.Introduction
Current antiparkinsonian oral drug therapies, with the do-
pamine (DA) precursor levodopa (L-dopa) remaining the
most eﬀective, allow remarkable symptomatic control over
the cardinal motor features of Parkinson’s disease (PD) in
the ﬁrst years after diagnosis, by restoring the character-
istic nigrostriatal DA deﬁcit. Unfortunately, the pharma-
cotherapeutic window shrinks over time, and treatment is
complicated by the onset of motor ﬂuctuations (“ON/OFF”
phenomena) and L-dopa induced dyskinesias (LIDs), while
signs such as balance disorders, gait freezing, autonomic
disturbances, dementia, or aﬀective changes, refractory to
dopaminergic substitution, appear [1–3]. Continuous deliv-
ery of the DA agonist apomorphine (subcutaneously) or
L-dopa (intraduodenally) and surgical strategies such as
deep brain stimulation (DBS) provide relief in advanced PD
patients with severe motor complications [4–6]. These ther-
apeutic advances, nevertheless, do not inﬂuence the under-
lying neurodegenerative process and have limited eﬀects
on L-dopa nonresponsive clinical manifestations, which are
now clearly recognized as causes of major disability in late-
stage PD [3, 7, 8]. Hence, there is a pressing demand for
innovative approaches. Cell replacement therapies and gene
transfer through viral vectors into the degenerated host
brain have been investigated as alternatives to surpass the
shortcomings ofconventionalsymptomatic treatment in PD.
Taken together, evidence accumulated so far has provided
promising results and proof-of-principle that therapeutic
beneﬁts can be achieved, but also generated several unre-
solved concerns and limitations regarding both these tech-
nologies. In this paper, we discuss a number of critical issues
that future clinical trials should clearly address before cell-
based and gene therapies are considered as clinically relevant
treatment options for PD.
2.Choosing theRightIntervention
2.1. Cell Replacement Strategies. Since the late 1980s, over
300–400 PD patients worldwide have received transplants2 Parkinson’s Disease
of human fetal ventral mesencephalic (VM) tissue, rich
in post-mitotic DA neurons. The experience accumulated
fromopen-labelstudiessuggestedsigniﬁcant clinicalbeneﬁts
across multiple parameters in patients receiving grafted cells
accompanied by a general reduction in pharmacological
requirements [9–11]. Two double-blind, placebo-controlled
transplantation trials showed variable eﬃcacy of transplants
and occurrence of side eﬀects, including “oﬀ medication” or
“graft induced” dyskinesias (GIDs) [12, 13]. Furthermore,
a decade after transplantation, it was observed that the PD
pathologic process might propagate from host to grafted
cells, as indicated by decrease in staining for the DA trans-
porter (DAT) and the presence of intracellular inclusions
identical to Lewy bodies [14–16]. Nevertheless long-term
follow-up of one of these trials showed consistent eﬃcacy
using both clinical and imaging outcome measures [17].
Retrospective analysis of clinical trials and further basic
science research have sought to explore factors explaining
variability in results of cell transplantation open-label series
and double-blind trials and determine whether the most
successful cases, which had L-dopa withdrawn and exhibited
major clinicalimprovement for severalyears, couldberepro-
ducible. A number of technical parameters regarding tissue
procurementandpreparation,suchastheageandnumberof
donorfetuses,graftdissectionprocedures,storagelengthand
conditions, tissue dissociation before transplantation (into
pieces or crude cell suspensions), or the use of ancillary
neuroprotective strategies to increase graft survival (i.e.,
glial-derived neurotrophic factor (GDNF), lazaroids), are
likely to have an important role [18–20]. It is therefore
highly possible that superior and consistent results can be
achieved with further optimization of the graft procedure
and overall transplant protocol. It has become evident that
future trials should attempt graft puriﬁcation by minimizing
the serotonergic (5-HT) component of the grafted tissue,
likelyto be involvedin thedevelopmentofGIDs,use surgical
procedures that give rise to the optimumdistribution of cells
over the putamen, and adopt an eﬀective mode of carefully
monitored immunosuppression for at least 6–12 months
post graft [18, 21].
Nevertheless the shortage of embryonic donor tissue,
diﬃculties in standardization of cell material (the age at the
time of abortion, exact number of donors per putamen)
as well as ethical concerns associated with the procurement
of tissue from aborted human fetuses make routine clin-
ical application for this type of cell replacement therapy
impractical. Alternative cell sources such as autografts of
sympathetic neurons from the adrenal glands or xenograft
tissue (porcine mesencephalic embryonic neurons) have
been abandoned because of discouraging clinical and graft
survival results and signiﬁcant side eﬀects [22–24].
Recent progress in the stem cell ﬁeld has provided impe-
tus to the cell replacement approach. Stem cells of human
origin, potentially able to provide an unlimited supply of
standardized DA neurons, may be considered as the most
promising future source for a cell-based therapy for PD [25].
Cells with the desired molecular, morphological, and elec-
trophysiological proﬁle of A9 substantia nigra DA neurons
can be generated from diﬀerent stem cell sources in vitro,
following various diﬀerentiation protocols, and can reverse
behavioural deﬁcits after transplantation in animal PD mod-
els. Embryonic stem cells (ESCs), neural stem cells (NSCs)
isolated from embryonic/fetal or adult brain, pluripotent
nonneuronal/mesenchymal stem cells (bone marrow, umbil-
ical cord), or the more recently discovered reprogrammed
somatic cellssuch as inducedpluripotentSC(iPS)ordirectly
induced neuronal (iN) cells represent potential alternative
sources for transplantable material, each having diﬀerent
advantages and disadvantages when considered for a clinical
based application (Table 1)[ 26–32].
The generation of these cells has highlighted the unre-
solved issue whether entirely pure DA cell populations will
be suﬃcient, since the nondopaminergic neurons and most
probably glial compartments present in the embryonic mes-
encephalic grafts used so far may be important for the dif-
ferentiation and function of the grafted DA neurons per se,
as well as constituting important cellular factories for
creating reparative microenvironment at the host’s brain
[33]. Irrespective of the cell origin, the methods of their
harvest, the number of cells available, the mean number of
cells injected and their biochemical characteristics will all
have to be standardized and sites certiﬁed and inspected to
ensuretheirclinicalgradebeforeparticipationinmulticentre
trial programmes.
At the present time fetal VM tissue still remains the
best standard against which to test future sources of cells
for dopaminergic cell replacement in PD. In this context,
a new European multicentre project, called TransEuro, was
recently launched to further investigate the optimization
of the collection, preparation, and storage of fetal tissue
for grafting, the selection of the optimal patient group for
grafting, evaluate the cause of GIDs, and conﬁrm the eﬃcacy
of the transplant technique.
2.2. Gene Therapy Approaches. Based on their functional
targets (direct stereotactic injection into striatal, nigral, or
subthalamicnucleus(STN)cells),andproposedmechanisms
of action, gene therapy approaches can be subdivided into
3 main categories: (a) restoration of DA synthesis capacity
(enzyme replacement), (b) basal ganglia circuit modula-
tion, and (c) disease modiﬁcation/neuroprotection through
trophic factors. All of these approaches have identiﬁed issues
in trial design relevant to future investigations.
Enzyme-replacement genetherapy inPD aims toprovide
an advantageoverperipherally administered L-dopathrough
restoration of a more physiological manner of dopamine
receptor stimulation and/or reduction in the side eﬀects that
accompany prolonged peripheral L-dopa administration.
These approaches rely on the use of 1 or more of the key
enzymes, namely, tyrosine hydroxylase (TH), aromatic L-
amino acid decarboxylase (AADC), and GTP-cyclohydro-
lase-1 (GCH1) to either replace DA directly (Prosavin), en-
hanceDAsynthesisfromL-dopa(AADC“prodrug”),orsup-
ply continuous DOPA delivery [34]. One concern is that
ectopic synthesis of DA in a cellular compartment without
vesicular storage and release mechanism for this neuro-
transmitter could result in multiple detrimental eﬀects, that
is, exacerbation of dyskinesias, or even degenerative eﬀectsParkinson’s Disease 3
Table 1: Comparison of tissue/cell sources for cell replacement strategies in PD.
Type of cell
Availability/
expandability/
proliferation
Capacity to
diﬀerentiate into
DA phenotypes
Tumor formation
potential
Ethical
concerns GID Major advantage
Fetal VM tissue +/− +++ − + + Clinical experience
Embryonic stem cells +++ ++ + ++ ? Expandability and
diﬀerentiation
Neural stem cells + + +/− +/− ? Opportunity of
autotransplantation
Mesenchymal somatic stem cells + +/− ? − ? Opportunity of
autotransplantation
Reprogrammed somaticcells ++ ++ + + ?
Easily approached
autologous source (e.g.,
ﬁbroblasts retrieved
from skin biopsies)
(?): unknown, (−): none, (+/−): poor, (+): some, (++): readily observable, (+++): extensive.
due to elevated cytosolic DA levels [35–37]. Preclinical data
and open-label studies have been promising with each of
these approaches without evidence of excessive dyskinesia
production but beneﬁcial eﬀects have been modest and
the dose of vector, rate of vector administration, and the
extentofcoverageoftarget tissue remain uncertain. Whether
recombinant adeno-associated virus-vesicular monoamine
transporter 2 (rAAV-VMAT2) should also be incorporated,
that would allow transduced cells to eﬀectivelyprocessDA, is
unclear [38–44].
Basal ganglia circuit modulation via gene therapy
attempts to inhibit abnormal activity in the STN by increas-
ing the expression of glutamic acid decarboxylase (GAD)
(responsible for GABA synthesis) using an AAV2 vector
encoding GAD injected into the STN mimicking the eﬀects
of DBS [45], and with the aim of delivering the same
eﬀectivesymptomaticreliefasDBSbutwithlowersideeﬀects
and with greater convenience through long-term symptom
alleviation without the need for battery changes. Results
from a phase II randomized, double-blinded, multicenter,
placebo-controlled trial showed modest beneﬁcial eﬀects
[46]; however long-term eﬃcacy and safety of this manip-
ulation remains to be proven, and the ideal trial, that is, a
randomised comparison of GAD gene therapy against STN
DBS may not be commercially appealing.
The overall goal for GDNF and Neurturin (an analogue
ofGDNF)genetherapyispreventionorslowing ofthe ongo-
ing degenerative processes, as well as strengthening and
supporting the dopaminergic phenotype of endogenous
nigrostriatalcells[47–49].Trophicfactortherapyisadisease-
modifying approach and therefore has the added advantage
overpharmacotherapy that it may theoretically alter the pro-
gression of the disease. The use of GDNF as a neuroprotec-
tant/neurorestorative agent has been extensively investigated
as a PD therapy [50–52]. Bilateral intra-putaminal injection
of AAV2-vector encoding a modiﬁed form of Neurturin
(CERE-120) did not demonstrate beneﬁt at 12 months al-
though an advantage was seen at 18 months in a double-
blind randomized controlled trial [53, 54]. This raised ques-
tions regarding the retrograde transport of the vector and
highlighted the need for adequate periods of follow-up in
these types of trials before breaking the blinding process.
A trial of Neurturin concomitantly administered to the
putamen and substantia nigra is currently underway.
There are thus a range of potential gene therapy tech-
niques that may confer beneﬁts to PD patients under certain
speciﬁc situations. The choice of the optimal intervention
may, therefore, be individually tailored to speciﬁc patient
groups (Table 2).
3.PatientSelection
Several clinical trials have been criticized for suboptimal
patient selection [12, 13, 52, 53] .W h i l et h e r ea r ei n e v i t a b l y
limitations regarding which patients can be recruited to
experimental trials of invasive and irreversible treatments,
predetermined inclusion and exclusion criteria have critical
impacts on the likelihood of a trial meeting its primary
endpoints.
Published series of PD patients who have received fetal
VM transplants indicated that the selection of patients
younger than 60 years of age, and having a less severe disease
(e.g., ≤ stage 3 Hoehn and Yahr scale), had better results at
12 months [12, 13]. With longer-term follow-up, these dif-
ferential eﬀects diminished [17]. However, both clinical and
animal studies suggest that residual spared circuitry provides
an elevated level of trophic support for newly grafted cells
to thrive [18, 55], therefore it would follow that severe PD
patients and those with widespread degeneration outside the
striatal target should probably be excluded (at least initially)
from cell and gene therapy trials. Furthermore, it is known
that severity of GIDs is related to severity of dopaminergic
deﬁcit which also plays a role in the development of LIDs,
therefore even though other mechanisms are undoubtedly
relevant, patients with severe L-dopa-induced dyskinesias
should probablynot be recruited to cell therapy trials [2, 56].
There is to some extent a balanced judgement that needs
to be made. With respect to any therapy with potential
disease-modifying eﬀects (cell replacement therapy or neu-
rotrophic factor gene therapy), it seems more sensible to4 Parkinson’s Disease
Table 2: Patient-centred comparison of gene therapy interventions for PD.
Gene therapy strategy Advantages Disadvantages Patient target group
Neurotrophic factor delivery Disease-modifying/neuroprotective
potential
Likely to cause structural and
functional eﬀects beyond the
intended targets
Early-stage PD
Prodrug approach
(i) Striatal DA synthesis dependent on
subsequent peripheral administration of
L-dopa → modulation of
(ii) Therapeutic eﬀect still within control
of the clinician
(i) Possibilityof accumulation of
DA in striatal neurons
(ii) Increased endogenous DA
production, without increased
vesicular dopamine storage,
could potentially exacerbate
dyskinesia
(i) More advanced-stage PD
with motor complications
(ii) Patients with inadequate
striatal AADC activity
Ectopic DA production
(i) Independent of peripheral L-dopa
(ii) Independent of endogenous AADC
activity
(i) More advanced-stage PD
with motor complications
(ii) Patients with inadequate
striatal AADC activity
Continuous DOPA delivery
strategy
(i) Site speciﬁc continuous DA—supply
(ii) Independent of peripheral L-dopa
Depends on suﬃcient
endogenous AADC activity
(i) More advanced-stage PD
with motor complications
(ii) Patients with suﬃcient
striatal AADC activity
Modulation of basal ganglia
activity
Proposed to mimic clinical results of
DBS, which has established clinical
eﬀectiveness
(i) Limited experience
(ii) Safety concerns due to
bilateral irreversible nature of the
technique
Same as DBS
target the disease in its earlier stages. On the other hand,
the use of experimental, invasive, irreversible techniques in
a group of people with relatively mild symptoms needs con-
sideration,inviewofthesmall butimportant risksassociated
with functional neurosurgery, although importantly these
risks tend to be less among younger people with less brain
atrophy. It is possible that very early-stage patients may lack
thelevelofdegenerationnecessary tostimulatetrophicfactor
release needed to support graft survival and outgrowth, al-
though there is only limited animal data to suggest this [55].
The degree of response to L-dopa is clearly of relevance
for any dopamine replacement based therapy. PD patients
withseveretremorthatisnonresponsive todopaminemight,
intheory,remainwithmajordisability,despiteexcellentgraft
survival and function or cell transfection, because of tremor
persistence. Exclusion of subjects without any dopaminergic
deﬁcits (SWEDDs) needs to be conﬁrmed through routine
F-dopa positron emission tomography (PET) or DAT single-
photon emission computed tomography (SPECT) imaging
at recruitment [57, 58]. Other debilitating symptoms in PD
are also caused by pathological changes in nondopaminergic
systems leading to postural instability and gait dysfunction,
dementia, and autonomic disturbances. Until it is known
how to repair these systems, patients in whom such features
are predominant should probably not undergo cell trans-
plantation or gene therapy.
Continuous DOPA delivery utilizes both vector-derived
TH and GCH1 but diﬀers signiﬁcantly from the Prosavin
approach in that it depends on endogenous striatal AADC
in the host brain for DA synthesis. This therapy therefore,
is likely limited to less-severely impaired patients with
suﬃcient endogenous AADC levels. In contrast, all other
genetherapy approaches couldbe appliedto a relatively wide
range population provided they exhibit a predominance of
DA responsive symptoms.
In addition to age, disease severity, L-dopa responsive-
ness, and comorbidity based inclusion/exclusion criteria, the
impact of these therapies on important genetic subgroups
of patients with predominantly motor deﬁcits needs to be
determined. Preoperative genotyping for common genetic
variants (e.g., parkin, LRRK2 subgroups) is to be recom-
mended to allow planned subgroup analyses for individuals
with Mendelian forms of PD.
4.StudyObjectives/Endpoints
The primary objective of either cell transplantation or gene
transfer paradigms is to demonstrate signiﬁcant improve-
ment across predetermined clinical parameters in a deﬁned
patient group [59]. For most gene therapy programmes the
objectiveremainsthedemonstrationofclinicalimprovement
ofspeciﬁcsymptoms, whileneurotrophicfactorgenetherapy
a n dc e l lt h e r a p ya i mt ob er e s t o r a t i v e .T h e s ed i v e r g e n ta i m s
both require robust measures of longitudinal quantitative
assessment.
The most widely accepted measure of PD severity is
the Uniﬁed PD Rating Scale (UPDRS-Movement Disorders
Society modiﬁed version) which can be rated in a practically
deﬁned “OFF” condition, that is, after 12 hours since last
dose of dopaminergic therapy. Accompanying this scale,
quantitative measurements of speed (timed tests) can also
add objectivity to the assessment of treatment response
over time [60]. However, the “OFF” medication evaluation
is a somewhat artiﬁcial condition, given that many drugs,
including L-dopa, are known to have additional “long dura-
tion eﬀects” [61]. Changes of the long-term response to
L-dopa patterns per se would be worth considering when
comparing pre- and post-intervention “OFF” medication
states, particularly in exogenous L-dopa-dependent gene
therapy approaches [62]. Furthermore, most patients spendParkinson’s Disease 5
the majority of their time in the “ON” medication state and
therefore“OFF”improvementsarelessrelevanttotheirusual
functional independence. In view of the diurnal variation
“ﬂuctuations” in PD motor control, common with periph-
eral L-dopa usage, diary data that summarises duration and
severity of “ON,” “OFF,” and dyskinetic time can be an
additional demonstration of meaningful improvement [63].
Diarydatacanhoweverbeofvariablequality,andtechnology
has been embraced to try and improve the reliability of data
obtained [64]. Objective measurement of “On drug” and
“Oﬀ drug” dyskinesia using validated scales and a consistent
protocol allows treatment-related changes to be objectively
and accurately quantiﬁed [65].
It has been suggested that time to reach other disease
milestones such as the Hoehn and Yahr scale might be
more appropriate simple measures from which to objectively
judge disease progression [66], and this might be of use
in trials of potentially disease-modifying approaches. Mea-
surement of time to develop axial or cognitive symptoms
would be of less value in dopamine replacement approaches.
Despite this, given that some nonmotor features of PD
can be DA responsive and others not, even the dopamine
replacement strategies should collect data and evaluate posi-
tiveornegative eﬀectsoftheireﬀectson a range ofsecondary
endpoints including the broader nonmotor aspects of the
disease, such as cognition, aﬀective changes, autonomic
symptoms,andsleepdisorders,byemployingvalidatedscales
[67].
Somefunctional neurosurgery interventionshavechosen
a patient oriented scale (PDQ-39) as the primary outcome
measure [68]. This assessment, in tandem with physician
derived assessments that systematically measure disease
severity, ensures that data of robust academic value is also
translated into meaningful resul t sa sp r i o r i t i s e db yp a t i e n t s .
Economic analyses, utilising tools such as Quality-Adjusted
Life Years (QALYs) or EQ-5D, can allow evaluation of cost-
eﬀectiveness over time and should routinely be incorporated
into trial design.
Biomarkersthatreﬂectdisease stateorratemayalsoserve
as surrogate endpoints in clinical trials. At present, there is
no biomarker that is suﬃciently well accepted to serve as a
primary endpointinaclinicaltrialofPDcellorgenetherapy.
The most relevant technologies available are the dopamin-
ergic imaging modalities, including measuring presynaptic
AADC activity using PET (18F-dopa) and the labelling of
thedopaminetrans port er(D A T)us ingSPECT[69,70].Such
neuroimaging endpoints have some advantages over clinical
markers, being more objective, more sensitive, particularly
in presymptomatic/early stages, however, may themselves
be aﬀected by drugs’ symptomatic eﬀects. The inclusion of
these measures early in trials of cell or gene therapies does,
nevertheless, provide important clues about the biological
eﬀectsof these treatments. In addition, the dataaccumulated
regarding the imaging and the eventual outcome of the
patients will help to deﬁne the utility of such imaging
methods in future studies. The major disadvantages are their
additional expense and the fact that most commonly used
imaging tools do not quantify the extrastriatal degenerative
processes of PD.
Long-term follow-up is mandatory within cell replace-
ment or gene therapy trial designs. These approaches should
not realistically be expected to induce rapid disease modiﬁ-
cationinPD.Apracticaldecisionneedstobemaderegarding
thedurationoffollow-upbeforebreakingtheblindindouble
blind trials. Even 12-month blinded follow-up may not
be suﬃcient [53, 54]. Moreover, such invasive treatments
must be shown to maintain therapeutic eﬀects and accept-
able long-term adverse event proﬁles on a long-term basis
(throughopen-labelextension)beforetheycanbeeligiblefor
consideration as therapeutic options, as evidenced already
[17].Indeed,since thesetreatments are likelyto permanently
change the biology of the nervous system, lifelong follow-up
of all treated patients is advised until substantial experience
is accumulated.
Another important aspect of this work is to demonstrate
the survival and maintenance of grafted neurons or the
gene transduction eﬃciency of viral vectors to the desired
targeted brain areas. Direct proof of such accomplishments
is not possible during the life of a patient. Long-term
improvementsofmotorfunctionsorreductionsindopamin-
ergic medications together with PET imaging ﬁndings may
be correlated against the survival of the graft and degree
of satisfactory gene transfer [12, 13, 17, 18, 53, 71].
Permissionforpostmortemexaminationshouldbediscussed
and obtained during life to enable routine examination
when participants die. The postmortem examination of the
grafted brains validates the clinical diagnosis of PD, also
directly shows the presence of the heterotopic grafted TH
neurons in the striatum, and allows a numerical estimate of
the number of surviving neurons (viability) of the striatal
volume, reinnervated by DA ﬁbres, with reciprocal synaptic
contacts with the host’s brain. It also shows the evidence of
immune events around the transplanted neurons [13]. In
PD cases, postmortem studies have validated the preclinical
experiments and the postulated dopaminergic reinnervation
of the striatum by grafted neurons [72–74]. Moreover such
histopathological studies can determine whether and to
which extent grafts are aﬀected by the PD pathologic process
and indicate the involved mechanisms [14–16]. They also
provide pathological evidence regarding the relationships
between transplantation protocols and adverse phenomena
such as GIDs [75].
Given that the occurrence of GIDs in a signiﬁcant subset
of grafted patients has been a major hurdle for further
development of cell-based therapies for PD [12, 13, 76], a
priority for future trials is to demonstrate that by reﬁning
transplantation protocols GIDs can be prevented. Notwith-
standing the several theories proposed, recent experimental
data have implied that neuronal composition of grafted
tissue, and graft derived 5-HT hyperinnervation in par-
ticular, is involved in the pathogenesis of GIDs. High 5-
HT to DA neurons and 5-HT transporters (SERT) to DAT
ratios, respectively, leading to a dysregulation of DA synaptic
levels, seem to be signiﬁcantly contributing to the devel-
opment of GIDs, and therefore, this evidence suggests that
achieving normal striatal 5-HT/DA and SERT/DAT ratios
following transplantation should be necessary to avoid
the development of GIDs [77]. According to these data,6 Parkinson’s Disease
11C-DASB PET, a marker of SERT availability, pre- and
post-transplantation, alongside with clinical assessment of
dyskinesias and histopathological data when available, could
serve as a useful functional imaging tool to monitorthe opti-
mization of transplantation techniques and patient selection
and lead to reproducible and marked clinical improvement
while escaping the troublesome complication of GIDs [78].
5.Data Analysis
When designing a clinical trial, the number of participants
required to reliably answer the clinical question should
be carefully considered. Sample size calculations require
estimates of eﬀect size and variance of that eﬀect size with
relation to the primary outcome measure [79]. This can of
course lead to impossibly high numbers given that, in novel
cell or gene therapies, estimates of eﬀect size and variance
may be crude with limited precision or may only exist for
outcome measures aside from the major variable of interest.
Statisticalrigour is at risk of being sacriﬁced in the face of the
need to perform novel, clinically relevant, and yet aﬀordable
trials. Phase II trials with low power or even pilot trials
with limited precision should involve experienced statistical
support during protocol development, funding application,
ethical review, and recruitment and not simply during data
analysis and manuscript preparation. This said, in a disorder
such as PD that invariably shows relentless progression,
short-term blinded comparisons can be complimented by
long-term open label follow-up which together can limit the
extent of inﬂuence due to placebo eﬀects and observer bias.
Choosing a cohort sample size is necessarily a ﬁne balance of
logistical and pragmatic/ethical considerations that includes
and takes account of experienced statistical advice. The
selection of appropriate analytical tests, multivariate models,
and thresholds for judging signiﬁcance emerge from this
careful planning.
6.ShamSurgeryImplementation
Double-blind placebo-controlled trial designs are the essen-
tial tools to establish the clinical eﬃcacy of any intervention
by minimising bias or placebo eﬀects. Cell replacement
or gene therapies for PD represent invasive techniques,
requiring direct surgical access to the site of delivery in the
brain. “Sham surgery”, the placebo approach taken in most
studies [12, 13, 53], thus, requires an elaborate performance,
during which many of the procedures involved in the
actualtreatmentaresimulated,oftenincludingsomeinvasive
element such as burr hole creation. Even though the actual
risk is quite low and medically signiﬁcant complications
are rare, these approaches are much more invasive than a
typical placebo and the risk of short-term pain, stress, and
disability during recovery is virtually certain, and therefore,
the use of sham surgery is not without ethical controversy
[80]. Protocols that involve “awake surgery” require an
elaboratepantomime tomaintain blinding suchthatpatients
remain uncertain regarding their treatment allocation. The
completeness of the blinding procedure should therefore be
routinely systematically recorded through patient interview.
Additional risks emerge in protocols requiring general
anaesthesia, immunosuppression therapy, and/or signiﬁcant
irradiation exposure for repeated functional imaging scans
during evaluation periods, necessary for maintaining the
blinding protocol. It is without doubt that substantial and
long-lasting placebo eﬀects can occur in PD trials, which
might beevenmorepronouncedwhen surgicalinterventions
are involved, however, some investigators doubtthe scientiﬁc
rationale for using sham surgery for neurotransplantation or
gene transfer studies, in the ﬁrst place [81, 82]. They argue
that PD is known to be a progressive degenerative disease
thatdoesnotimprovein itsnormalnaturalhistory, andmost
likely any placebo eﬀects will wane on the long term. Given
that PD trials often involve subjective rating scales as the
primary outcome measure, which are vulnerable not only
to placebo eﬀects, but to other forms of bias as well, it is
currently diﬃcult to escape the demand for sham surgery
controlled trials. Still, the use of double-blindsham-surgery-
controlled trials should be justiﬁed by suﬃcient preclinical
and open-label evidence and considered once neurobiolog-
ical and technical parameters are standardized. The ethical
integrity of sham surgery implementation depends on the
ability of the investigators to inform potential subjects about
theproceduresandtherisksinvolved.Inevitablyproofofeﬃ-
cacy for any of the current approaches will compare eﬀects
against “placebo” or sham surgery to enable blinding but
given the proven eﬀectiveness of existing proven functional
neurosurgery—for example, STN DBS, future trials of novel
symptom relieving interventions might require comparison
against these “conventional” treatment approaches albeit
necessarily in an open label manner.
7.CurrentChallengesandFuturePerspectives
The experimental ﬁeld of restorative neurology continues to
advance with implementation of cell replacement or gene-
transfer-based approaches to treat patients with PD. Both
strategies have generated a consensus demonstrating their
capacity for structural and molecular brain modiﬁcation in
the adult brain. The source of tissue/cells remains a major
subject under consideration for future clinical trials and it is
still unknown which cell type(s) may oﬀerthe ideal substrate
for a transplantation-based protocol in PD. With respect
to gene therapy paradigms, the optimal vector, therapeutic
protein, and target site remain to be deﬁned, as does, of
course the risk of adverse eﬀects associated with both these
techniques.
The requirements for either cell or gene therapies to be-
come clinically competitive treatments for PD are very high.
Relief of motor symptoms can be achieved, to a variable
extent, by oral medicationsupplementedby alternative route
drug delivery (e.g., apomorphine injections and intrajejunal
L-dopa gel)orDBSforadvanced-stage disease. Cell and gene
therapy treatments will, therefore, have to demonstrate an
advantage either in terms of neuroprotection/repair, or in
terms of clinical eﬃcacy or safety over both currently avail-
able medical and surgical alternatives. The absence of im-
planted hardware and no need for recurrent battery changes,
percutaneous tubes and pumps may represent an advantageParkinson’s Disease 7
overtheseoptionsintermsofpatientconvenience.Currently,
thesafety, eﬃcacy,anddisease-modifying capacityofcelland
gene therapies remain to be unequivocally proven, and the
commercial costs and necessary surgical expertise for their
successful delivery will inevitably limit their availability in
many countries.
Far fewer treatment options address the nonmotor as-
pects of PD, such as dementia, neuropsychiatric symptoms,
autonomic failure, and sleep abnormalities, which dominate
the clinical, caregiver, and ﬁnancial burden in advanced
stages of the disease [3, 8]. It is tempting to speculate that
restoration of the nigrostriatal DA system might physiolog-
ically restore DA innervation to extrastriatal regions and
thereby improve deﬁcits related to cortical and brain stem
dopamine deﬁciency or could even have consequences that
extend to the nondopaminergic neurons. It is possible that
those nonmotor symptoms with a focal subcortical anatom-
i c a lb a s i sr e p r e s e n tf u r t h e rs y m p t o m st h a tm a yr e s p o n dt o
targeted gene therapy, while transplantation of diﬀerent cell
types (e.g., glia) might provide more widespread beneﬁts
than are currently contemplated [83, 84].
The number of parameters that will conceivably inﬂu-
ence the outcome of clinical trials of cell or gene therapies is
very high. We are currently at a stage where an “explanatory”
approach is required to demonstrate that these interventions
canhaveusefuleﬀectsinthehandsofveryexperiencedteams
recruiting highly selected patients. Whether any positive
ﬁndings can be subsequently reproduced on a “pragmatic”
basis with broader patient inclusion criteria, and in anticipa-
tion of inevitable technical advances and reﬁnement of sur-
gicalparameters will becritical intermsoffuture widespread
adoption of any of these interventions.
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